SCHEMBL707095

SCHEMBL707095

CC[Si](Br)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.35
ESR1 P03372 2/20 0.34
ESR2 Q92731 1/20 0.34
PSIP1 O75475 1/20 0.32
ALDH1A1 P00352 3/20 0.32
TSHR P16473 2/20 0.32
TRPA1 O75762 1/20 0.32
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
LMNA P02545 2/20 0.31
ALOX12 P18054 1/20 0.30
ACHE P22303 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
PTGS2 P35354 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704482 0.80 TP53 (0.35) TP53MAPTESR1ESR2PSIP1
SCHEMBL705955 0.79 TP53 (0.38) TP53MAPTESR1ESR2PSIP1
SCHEMBL706448 0.79 TP53 (0.38) TP53MAPTESR1ESR2PSIP1
SCHEMBL708577 0.78 ALDH1A1 (0.35) MAPTESR1ESR2ALDH1A1TSHR
SCHEMBL703222 0.78 ALDH1A1 (0.35) MAPTESR1ESR2ALDH1A1TSHR
SCHEMBL18108273 0.77 SIGMAR1 (0.37) TSHRPTGS2
SCHEMBL988676 0.75 NR1H2 (0.43) TP53MAPTESR1ESR2PSIP1
SCHEMBL705023 0.74 ALDH1A1 (0.32) MAPTESR1ESR2ALDH1A1TSHR
SCHEMBL707662 0.74 ALDH1A1 (0.32) MAPTESR1ESR2ALDH1A1TSHR
SCHEMBL18108341 0.73 KCNH2 (0.42) TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238771-A1 SUPPORTED RARE EARTH CATALYSTS AND CATALYTIC CH BORYLATION OF HYDROCARBONS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2024-07-18 US claimed
US-20240238771-A1 SUPPORTED RARE EARTH CATALYSTS AND CATALYTIC CH BORYLATION OF HYDROCARBONS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2024-07-18 US disclosed
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
EP-2650319-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND Daicel Corporation (JP) 2013-10-16 EP disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
US-8124239-B2 Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same FUJITSU LIMITED (JP) 2012-02-28 US disclosed
US-20100155121-A1 SILICA FILM FORMING MATERIAL, SILICA FILM AND METHOD OF MANUFACTURING THE SAME, MULTILAYER WIRING STRUCTURE AND METHOD OF MANUFACTURING THE SAME, AND SEMICONDUCTOR DEVICE AND METHOD OF MANUFACTURING THE SAME FUJITSU LIMITED (JP) 2010-06-24 US disclosed
US-7659357-B2 Precursor organosilicon polymer of 1,2-Bis(dimethylethoxysilyl)ethane, 1,4-bis(dimethylethoxysilyl)benzene, tetraethoxysilane, methyltriethoxysilane, phenyltriethoxysilane; dielectric (DE) films having etching/chemical/moisture resistance; adhesion; low DE constant; minimal wiring delay; high speed FUJITSU LIMITED (JP) 2010-02-09 US disclosed
US-20070026689-A1 Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same FUJITSU LIMITED (JP) 2007-02-01 US disclosed
US-20050124646-A1 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-09 US disclosed
US-5496727-A Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 US disclosed
EP-0184162-B1 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-04-27 EP disclosed
US-5266692-A Autoimmune FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-11-30 US disclosed
US-5254562-A Autoimmune FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1993-10-19 US disclosed
CN-1020853-C Pharmaceutical composition containing tricyclic compound or salt thereof FUJISAWA PHARMACEUTICAL CO (JP) 1993-05-26 CN disclosed
US-5110811-A Antibody inhibitors FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-05-05 US disclosed
US-4956352-A TREATING AUTOIMMUNE DISEASES, RESISTANCE TO TRANSPLANTATION, INFECTIONS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-09-11 US disclosed
US-4929611-A ANTIBODY INHIBITORS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-29 US disclosed
US-4894366-A Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-01-16 US disclosed
EP-0184162-A2 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238771-A1 SUPPORTED RARE EARTH CATALYSTS AND CATALYTIC CH BORYLATION OF HYDROCARBONS HAO2, SCO2, SOD1 TP53 4264/4885MAPT 4284/4885ESR1 465/4885
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 TP53 3501/4885MAPT 3379/4885ESR1 2638/4885
US-20050124646-A1 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same OTC, OAT, SLC11A2 TP53 4310/4885MAPT 3641/4885ESR1 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.